Iliac cancellous bone in drug addicts: A histomorphometric study

Journal of Forensic Sciences

Volumn 44, Issue 2, 1999, Pages 249-252

  Schiwy Bochat, Karl Heinz ^a   Lemke, Ralf ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Bone histomorphometry; Cancellous bone; Drug abuse; Forensic pathology; Forensic science; Substance abuse

Indexed keywords

DIAMORPHINE;

ADULT; ARTICLE; BONE BIOPSY; BONE DEMINERALIZATION; BONE EROSION; BONE MASS; BONE STRUCTURE; CANCELLOUS BONE; CLINICAL ARTICLE; DRUG DEPENDENCE; DRUG OVERDOSE; FEMALE; HUMAN; ILIAC BONE; INTERMETHOD COMPARISON; MALE; METABOLIC BONE DISEASE; OSTEOID; OSTEOMETRY; PRIORITY JOURNAL; TRABECULAR BONE;

EID: 0032998097     PISSN: 00221198     EISSN: None     Source Type: Journal    
DOI: 10.1520/jfs14448j     Document Type: Article

References (33)

1. Melton III LJ, Riggs BL. Clinical spectrum. In: Riggs BL, Melton III, LJ editors. Osteoporosis. New York: Raven Press, 1988; 155-79.
2. Spencer H, Rubio N, Rubio E, Indreika M, Seitam A. Chronic alcoholism. Frequently overlooked cause of osteoporosis in men. Am J Med 1986;80:393-7.
3. Karch SB. The pathology of drug abuse. 2nd ed., Boca Raton: CRC Press, 1996.
4. Swaab DF, Martin JT. Functions of alpha-melanotropin and other opiomelanocortin peptides in labour, intrauterine growth and brain development. Ciba Found Symp 1981;81:196-217.
5. Roy S, Loh HH. Effects of opioids on the immune system. Neurochem Res 1996;21:1375-86.
6. Spagnolli W, Torboli P, Mattarei M, DeVenuto G, Marcolla A, Miori R. Calcitonin and prolactin serum levels in heroin addicts: study on a methadone treated group. Drug Alc Depend 1987;20: 143-8.
7. Tagliaro F, Capra F, Dorizzi R, Luisetto G, Acordini A, Renda E, et al. High serum calcitonin levels in heroin addicts. J Endocrinol Invest 1984;7:331-3.
8. Locker FG. Hormonal regulation of calcium homeostasis. Nurs Clin North Am 1996;31:797-803.
9. Margolis RN, Canalis E, Partridge NC. Invited review of a workshop: anabolic hormones in bone: basic research and therapeutic potential. J Clin Endocrinol Metab 1996;81:872-7.
10. Birkenhäger-Frenkel DH, Courpron P, Hüpscher EA, Clermonts E, Coutinho MF, Schnitz PIM, et al. Age-related changes in cancellous bone structure. Bone Miner 1988;4:197-216.
11. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Min Res 1987;2: 595-610.
12. Parfitt AM, Mathews CHE, Villanueva AR, Kleerekoper M. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. J Clin Invest 1983;72:1396-409.
13. Pedrazzoni M, Vescovi PP, Maninetti L, Michelini M, Zaniboni G, Pioli G, et al. Effects of chronic heroin abuse on bone and mineral metabolism. Acta Endocrinol 1993;129:42-5.
14. Schnabel A, Reuhl J, Wicht H, Wachenfeld I, Wagner M, Bratzke H. Morphometrische Analyse der Wirbelkörperspongiosa bei i.v. Drogenkonsumenten. In: Althoff H, editor. Rechtsmedizin von A-Z. Herzogenrath: Murken-Altrogge, 1995;141.
15. Melsen F, Mosekilde L. Tetracycline double-labeling of iliac trabecular bone in 41 normal adults. Calcif Tissue Res 1978;26: 99-102.
16. Ballanti P, della Rocca C, Bonucci E, Milani S, Io Cascio V, Imbimbo B. Sensitivity of bone histomorphometry in the diagnosis of metabolic bone diseases. Path Res Pract 1989;185:786-9.
17. Eriksen EF, Steiniche T, Mosekilde L, Melsen F. Histomorphometric analysis of bone in metabolic bone disease. Endocrinol Metab Clin North Am 1989;18:919-54.
18. Parisien MV, McMahon D, Pushparaj N, Dempster DW. Trabecular architecture in iliac crest bone biopsies: infra-individual variability in structural parameters and changes with age. Bone 1988;9: 289-95.
19. Dempster DW, Ferguson-Pell MW, Mellish RW, Cochran GV, Xie F, Fey C, et al. Relationships between bone structure in the iliac crest and bone structure and strength in the lumbar spine. Osteoporosis Int 1993;3:90-6.
20. Krempien B, Lemminger F-M, Ritz E, Weber E. The reaction of different skeletal sites to metabolic bone disease - a micromorphometric study. Klin Wschr 1978;56:755-9.
21. Malpe R, Baylink DJ, Linkhart TA, Wergedal JE, Mohan S. Insulin-like growth factor (IGF)-I, -II, IGF binding proteins (IGFBP)-3, -4, and -5 levels in the conditioned media of normal human bone cells are skeletal site-dependent. J Bone Miner Res 1997;12:423-30.
22. Scheidegger C, Zimmerli W. Infectious complications in drug addicts: seven-year review of 269 hospitalized narcotics abusers in Switzerland. Rev Infect Dis 1989;11:486-93.
23. Andersen K, Bennedbaek FN, Hansen BL. Septic arthritis in intravenous drug abuse. Ugeskr Laeger 1994;156:3876-80.
24. Espersen F. Identifying the patient risk for Staphylococcus aureus bloodstream infections. J Chemother 1995;7 Suppl. 3:11-7.
25. Sapico FL, Montgomerie JZ. Vertebral osteomyelitis in intravenous drug abusers: report of three cases and review of the literature. Rev Infect Dis 1980;2:196-206.
26. Roy S, Ramakrishnan S, Loh HH, Lee NM. Chronic morphine treatment selectively suppresses macrophage colony formation in bone marrow. Eur J Pharmacol 1991;195:359-63
27. Loh HH, Smith AP, Lee NM. Effects of opioids on proliferation of mature and immature immune cells. Adv Exp Med Biol 1993; 335:29-33.
28. Beyer HS, Parfitt AM, Mei Shu Shih, Anderson Q, Heath H III. Idiopathic acquired diffuse osteosclerosis in a young woman. J Bone Miner Res 1990;5:1257-63.
29. Villareal DT, Murphy WA, Teitelbaum SL, Arens MQ, Whyte MP. Painful diffuse osteosclerosis after intravenous drug abuse. Am J Med 1992;93:371-81.
30. Whyte MP, Teitelbaum SL, Reinus WR. Doubling skeletal mass during adult life: the syndrome of diffuse osteosclerosis after intravenous drug abuse. J Bone Miner Res 1996;11:554-8.
31. Beyer HS, Anderson Q, Mei Shu Shih, Parfitt AM, Heath H III. Diffuse osteosclerosis in intravenous drug abusers. (letter) Am J Med 1993;95:660-1.
32. Whyte MP, Murphy WA, Villareal DT, Teitelbaum SL, Arens MQ. Reply to letter. Am J Med 1993;95:661-2.
33. Khosla S, Hassoun A, Heath H III. Osteosclerosis in intravenous drug abusers. The Endocrinologist 1995;5:339-43.